Unless new drugs show real progression against current standards of care, market uptake can be slow, the margin of error thin — and yet, companies must maintain growth that shareholders expect.
In this compilation of four in-depth, data-rich reports from Pharmaceutical Executive, you'll learn a new set of metrics already allowing companies to align their strategies around the push for greater profitability, putting them on the right track.
Review how the highly competitive Pharma 2.0 world makes it more difficult to create true product differentiation, especially in the pre-launch phase. Find how a strong physician engagement "pull" through strategy can deliver major sales gains throughout the product life cycle.
Discover how to communicate a myriad of consistent and supporting messages in plain language, tailored to multiple types of stakeholder segments — and how the most effectively adapted companies focus on accomplishing it sooner than rival firms.